Company intelligence / Profile preview

Annoviant

Alpharetta, Georgia, United States

Ownership: Private
Development stage: Other

Overview

Annoviant's TxGuard™ platform offers a regenerative tissue implant for pulmonary valve repair in pediatric congenital heart disease, demonstrating preclinical and grant-supported promise for improved durability, biocompatibility, and reduced re-surgery rates. The NIH has provided several phases of funding, including Phase IIb in 2024, validating technology that resists thrombosis and calcification while promoting host integration and remodeling.

Therapeutic areas: Cardiovascular
Modalities: DeviceRegenerative tissue innovation
Industry: Implantable Medical Devices

Partnerships

Pediatric Device Consortiums (3 of 5 FDA-funded)Children’s Healthcare of AtlantaBoston Children’s HospitalChildren’s Hospital of PhiladelphiaThe Center for MedTech Excellence (Georgia Tech)

Beyond the preview

Go deeper on Annoviant.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Annoviant.

Explore the full profile